172 related articles for article (PubMed ID: 31960603)
21. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
Striegel H; Rössner D; Simon P; Niess AM
Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
[TBL] [Abstract][Full Text] [Related]
22. Combinatory in vitro effects of the β2-agonists salbutamol and formoterol in skeletal muscle cells.
Piribauer M; Jiang L; Kostov T; Parr M; Steidel S; Bizjak DA; Steinacker JM; Diel P
Toxicol Lett; 2023 Apr; 378():10-18. PubMed ID: 36822333
[TBL] [Abstract][Full Text] [Related]
23. Effects of β
Vélez EJ; Balbuena-Pecino S; Capilla E; Navarro I; Gutiérrez J; Riera-Codina M
Comp Biochem Physiol A Mol Integr Physiol; 2019 Jan; 227():179-193. PubMed ID: 30347245
[TBL] [Abstract][Full Text] [Related]
24. Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Walters EH
Drug Test Anal; 2019 Jul; 11(7):950-956. PubMed ID: 30865387
[TBL] [Abstract][Full Text] [Related]
25. Beta
Hostrup M; Reitelseder S; Jessen S; Kalsen A; Nyberg M; Egelund J; Kreiberg M; Kristensen CM; Thomassen M; Pilegaard H; Backer V; Jacobson GA; Holm L; Bangsbo J
J Physiol; 2018 Sep; 596(17):4121-4139. PubMed ID: 29968301
[TBL] [Abstract][Full Text] [Related]
26. Hypertrophic effect of inhaled beta
Jessen S; Onslev J; Lemminger A; Backer V; Bangsbo J; Hostrup M
Scand J Med Sci Sports; 2018 Oct; 28(10):2114-2122. PubMed ID: 29777633
[TBL] [Abstract][Full Text] [Related]
27. Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.
Cazzola M; Donner CF
Drugs; 2000 Aug; 60(2):307-20. PubMed ID: 10983735
[TBL] [Abstract][Full Text] [Related]
28. Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Drug Test Anal; 2012 Jun; 4(6):449-54. PubMed ID: 22447497
[TBL] [Abstract][Full Text] [Related]
29. beta2-Agonists at the Olympic Games.
Fitch KD
Clin Rev Allergy Immunol; 2006; 31(2-3):259-68. PubMed ID: 17085798
[TBL] [Abstract][Full Text] [Related]
30. β2-agonist therapy in lung disease.
Cazzola M; Page CP; Rogliani P; Matera MG
Am J Respir Crit Care Med; 2013 Apr; 187(7):690-6. PubMed ID: 23348973
[TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical treatment of asthma symptoms in elite athletes - doping or therapy?
Backer V; Lund T; Pedersen L
Scand J Med Sci Sports; 2007 Dec; 17(6):615-22. PubMed ID: 18093034
[TBL] [Abstract][Full Text] [Related]
32. [Medication, athletes and doping regulations].
Hartgens F
Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
[TBL] [Abstract][Full Text] [Related]
33. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.
Haase CB; Backer V; Kalsen A; Rzeppa S; Hemmersbach P; Hostrup M
Drug Test Anal; 2016 Jul; 8(7):613-20. PubMed ID: 26044066
[TBL] [Abstract][Full Text] [Related]
34. As-needed inhaled beta2-adrenoceptor agonists in moderate-to-severe asthma: current recommendations.
Cockcroft DW
Treat Respir Med; 2005; 4(3):169-74. PubMed ID: 15987233
[TBL] [Abstract][Full Text] [Related]
35. Antagonism of long-acting beta2-adrenoceptor agonism.
Lipworth BJ
Br J Clin Pharmacol; 2002 Sep; 54(3):231-45. PubMed ID: 12236842
[TBL] [Abstract][Full Text] [Related]
36. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
37. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
Ni Chroinin M; Greenstone IR; Danish A; Magdolinos H; Masse V; Zhang X; Ducharme FM
Cochrane Database Syst Rev; 2005 Oct; (4):CD005535. PubMed ID: 16235410
[TBL] [Abstract][Full Text] [Related]
38. Sports drug testing using complementary matrices: Advantages and limitations.
Thevis M; Geyer H; Tretzel L; Schänzer W
J Pharm Biomed Anal; 2016 Oct; 130():220-230. PubMed ID: 27040951
[TBL] [Abstract][Full Text] [Related]
39. Hormone abuse in sports: the antidoping perspective.
Barroso O; Mazzoni I; Rabin O
Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
[TBL] [Abstract][Full Text] [Related]
40. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
Gosetti F; Mazzucco E; Gennaro MC; Marengo E
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
